Larimar Therapeutics, Inc. (LRMR) Misses Q4 EPS by 24c
Tweet
Share
E-mailGet Alerts LRMR Hot Sheet
Join SI Premium – FREE
Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q4 EPS of ($0.73), $0.24 worse than the analyst estimate of ($0.49).
For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA lists top 5 themes driving next $1tn in incremental semi sales
- Silo Pharma reports nine-month stability data for SPC-15 PTSD drug
- Safe Pro wins $1.3M U.S. Army subcontract for AI landmine detection
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
